<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680326</url>
  </required_header>
  <id_info>
    <org_study_id>Interface, vitreomacular</org_study_id>
    <nct_id>NCT03680326</nct_id>
  </id_info>
  <brief_title>Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>Influence of Intravitreal Anti-vascular Endothelial Growth Factor Administration on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Hietzing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Hietzing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      To assess the influence of intravitreal anti-vascular endothelial growth factor (anti-VEGF)
      administration on vitreomacular interface- and retinal morphology in eyes with neovascular
      age-related macular degeneration (AMD) and to identify morphological markers potentially
      influencing disease prognosis.

      Methods:

      43 patients (51 eyes) with treatment naïve neovascular AMD subsequently treated with
      Bevacizumab 1.25mg (in 0.05ml of solution) were monitored until month 12 of follow-up.
      Following a loading dose of 3 monthly intravitreal anti-VEGF injections, patients were
      treated as-needed [pro re nata (PRN)]. Functional and morphological changes were assessed
      using Spectral Domain Optical Coherence Tomography (SD-OCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective study included 43 treatment-naive patients (51 eyes) with neovascular AMD
      over the course of 12 months. Patients were treated with a loading dose of 3 initial monthly
      anti-VEGF injections (Bevacizumab 1.25mg in 0.05ml of solution-Avastin®) and were followed
      monthly until year 1. Re-treatment was performed if needed (pro re nata-PRN) as previously
      reported.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2015</start_date>
  <completion_date type="Actual">April 14, 2018</completion_date>
  <primary_completion_date type="Actual">March 22, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>visual acuity testing was performed</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Vitreomacular Interface</condition>
  <arm_group>
    <arm_group_label>OCT</arm_group_label>
    <description>only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>only OCT</description>
    <arm_group_label>OCT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        treatment-naive patients with neovascular AMD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - diagnosis of treatment-naive neovascular AMD

        Exclusion Criteria:

          -  any treatment with other anti-VEGF agents than Bevacizumab in the follow-up period

          -  any other diseases leading to macular edema

          -  prior vitrectomy

          -  uveitis

          -  retinal or corneal laser surgery

          -  high myopia (&gt;6dpt)

          -  preceding eye trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>66 Years</minimum_age>
    <maximum_age>98 Years</maximum_age>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Hietzing</investigator_affiliation>
    <investigator_full_name>Dr. Clara Wernigg</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

